{"name":"Silence Therapeutics plc","slug":"silence-therapeutics-plc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Atu027","genericName":"Atu027","slug":"atu027","indication":"Other","status":"phase_1"},{"name":"Atu027 & gemcitabine in treatment arm 1","genericName":"Atu027 & gemcitabine in treatment arm 1","slug":"atu027-gemcitabine-in-treatment-arm-1","indication":"Other","status":"phase_1"},{"name":"SLN124","genericName":"SLN124","slug":"sln124","indication":"Other","status":"phase_1"},{"name":"SLN360","genericName":"SLN360","slug":"sln360","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Atu027","genericName":"Atu027","slug":"atu027","phase":"phase_1","mechanism":"Atu027 uses RNA interference to silence protein kinase N3 (PKN3) expression in tumor blood vessels, inhibiting tumor growth and metastasis.","indications":[],"catalyst":""},{"name":"Atu027 & gemcitabine in treatment arm 1","genericName":"Atu027 & gemcitabine in treatment arm 1","slug":"atu027-gemcitabine-in-treatment-arm-1","phase":"phase_1","mechanism":"Atu027 uses RNA interference to silence PKN3 expression, potentially inhibiting cancer cell metastasis, while gemcitabine disrupts DNA synthesis.","indications":[],"catalyst":""},{"name":"SLN124","genericName":"SLN124","slug":"sln124","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SLN360","genericName":"SLN360","slug":"sln360","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBTR0JWM1E0X3VGQlNWYTRzU3FWNm96eVppU3drUHVhT09TRzlkVVFsSjVMTzN1VlUyalBxd3hTTE9EeFNHRm1iOVRobUU5VkV2NVZ0dXhIQXZPdm1leUltaUtjUy1KT1NubW1odw?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Silence Therapeutics Plc (SLN) - Stock Titan","headline":"If You Invested $1,000 in Silence Therapeutics Plc (SLN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNNXJWYjc1WFJIcE11dTV2UHBrWjJZcl95ak16ODF1SU9Ob1lOb2NYeXhfdGlYQTAtSzA1NFFZbDFTcEUyNjJXU3lQOWlsOEdWZmtaRHpLYnJfWFQtZWYxbWp0a2picTJaNDg2TTl0Q0x2dEFvcDRLMVJFVzUzblRVQ0RYUEtHSW1YNnJrdGl1MWtoZC1TSXBfRk1KU1FyUQ?oc=5","date":"2026-02-24","type":"pipeline","source":"Share Talk","summary":"N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics - Share Talk","headline":"N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOb2FORjc0bGJIcWNyc0JlNlozYkRudHpaRnhwdmw3U2tZSjhSVmhMSlNiQVc3ekd1N0VwRHhsUWJ2ZEZHYTNmYW5LQzZBRFNXcjk5UmdtNDJTYnN5Um9TaFRZNVZqOEJXMlRLLXdGLUhRV2I4UUtodmFDVnlINUprT0p0YU4yb0RNcTFUYVZiTGNuQjhuaDRXdE9nVkJMR2w4MWxwOEp4V0YtNUVKVWtWOG1MUVJrWkdjRUxkeDN1LWROWFNZTTZnd20xNXM4T3F1VlBLbG93Vm5zRXM4UEY0Uk53TERLUFVpRW9B0gHwAUFVX3lxTE00bEY2ZWhZa1p2M0xpQno1NmlWT1RmaEZ6RmVNWkRsT1dNTEk2dkZVVnd2bE1ZdnFGeGloelJZWU1kMnd3ZEtPUEhrQnROb1RPY20wQ2hrd0RpVGtDT002SEhYMWZRYklzZVdCSEVDQkVNQjNSbndZUHdBcVNhOW9xaWExQXFycjBwcnBFeTZmY1QxVElHRUlWQVBsQi1ZOTJpV0hsY2VFN1hoRURKOVNuS0NXal9yZTZFOEsxNDUteU5aT0tpOGVlR2JqOGprUmlPNFk0VFJTZ3l6WmFtOTFTcTBGQktjM0JaNHdHYm9XLQ?oc=5","date":"2026-02-19","type":"pipeline","source":"simplywall.st","summary":"Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - simplywall.st","headline":"Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-05","type":"earnings","source":"simplywall.st","summary":"Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive - simplywall.st","headline":"Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOcVVIMzQ4cHVhaGx4WFZoTkxKZkl1d1RFcGRENFJMbDNYZjVQVWZIWlNWSlZIM21fN0ZfVHd1cjVkQ2lsaHNJcE42TXFrUl92TWFfUS1LNDdVYW04cktMUTRwajhnRms3eGlXcDZYbmhwUjdNQjVOSFpHamVCb1NGUEg3eXFQR18ySGxGaVdPVjV0a3NjQjFScElOakNlYWdrZWJJSXRMSjZzNDFMeXdWVVd0ZTB4ZFQzSlNRSlBjMlR1RVAtUWFBT01fc25RbTJ5akxlTVU4elp3X0FwbUQ3NdIB5gFBVV95cUxPcXNOa1docTlXcjI3cHFacWROQ1RuWURBSGQ0NF9CUWRUNXpGNGVueUJ2aWttRUdPS0JrSmh1V1JFRDlYTDc1NmdUZU1WVkNEWjNOSEV2UXVOSUNER0NEWVVvRk1CR1JwMWtibm5HOXFCQ2ZRZzlhcVROc0NYNTVsU2JCVW5kcFF1YW1tNVhlRndlZjlKTC1idUhWMlRIVmhTZF9iQnA0cE5TOXUtYWhJT0JVQ3ZCOFh1YmJUeE56Qmx1Vktxa09aNjE1WjIzWlQ1Q3NxX1pNZ3ZJejEyVjBLaFNfWU9VUQ?oc=5","date":"2026-01-10","type":"pipeline","source":"simplywall.st","summary":"Silence Therapeutics Insider Ups Holding During Year - simplywall.st","headline":"Silence Therapeutics Insider Ups Holding During Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPa2VRaUpIdzdBYzBhX1JZMjJOcnhudnJNcVQwd2w1SnZyYVBpR3VrQmp4dHg3dlRuUm1jNjVvOU9ISkRKMld5MGJrZXowLWJVX2xZbGtDYlpEejJ6WTUySHYxLUs3UUdSOGxIMW9GTm9Jbkh2YmNoNm5Gcm9udFlvTXN4SEQ?oc=5","date":"2025-12-28","type":"pipeline","source":"StocksToTrade","summary":"Biodexa Pharmaceuticals Faces Market Challenges as Stocks Decline - StocksToTrade","headline":"Biodexa Pharmaceuticals Faces Market Challenges as Stocks Decline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNOGhxbGVPY3pDV0hkZXNqY2lCRVhDQnhLcWtzS1haNGg4Q3pVUFRtek5tcS1xQm5zcWZSamRHelY5VmhSdVpRcWdrUU9VdHVsZWl5TnVVUlNsZy1VRUNKTGdrMklxSVFFWVBsZXNFMjVGS0JvM2lVMzRRSkNoS0NSdnc0cDdlN2FsVWdiQzk1OVVMbDd5WG9Iemw4eHJCTW1oZVdfdzBLTFByT2lQZFpRNTRHYm8zMTNaVG9rYWNfUkZPWVZjajVISGs4NE02RUEtcENpYWFpZzFpX1JYdUxMd1hn?oc=5","date":"2025-12-18","type":"pipeline","source":"Bioprocess Online","summary":"Alnylam Announces 250M Investment To Expand US Manufacturing Capacity In Massachusetts For RNAi Therapeutics - Bioprocess Online","headline":"Alnylam Announces 250M Investment To Expand US Manufacturing Capacity In Massachusetts For RNAi Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE91VXhkTDJBZ3pvbGhCQVYtRWNpOWtRUXJNOUFnZjRnMnRhbDNCU1Q1VGZqWW8taTNfMVNLTkhDaF9jeGFSTF9qM2hpaU1MS2VPLVpOdllzU0VUT2dUQUg2b2J3eXc?oc=5","date":"2025-06-23","type":"pipeline","source":"Market.us","summary":"RNA Based Therapeutic Market Size, Share | CAGR Of 17.7% - Market.us","headline":"RNA Based Therapeutic Market Size, Share | CAGR Of 17.7%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOVEJRbFlxSjJaUEpjNmJ1VzR1cVhMNmpzSXRZVmdPSjd6Ylc0T3hvODg3WkNGMVdQa1pKUFRST0lDbTl6Z0lGbm1lWnhoMll2aGVyMHpXZjJQN2ZTLVZqS19fdkhuVGRxUDdaaU42dnFrUWlFUUZicWUtZE4xbEphVmdwQm85MDVCcnJ4dzdoWUppZldzNW8yODdXMDNPSXptWWNrUWg0QWNOVUhtbHZETVNkZjRyVWhDOGpRS0QtR3d3MDZXTTFlaVRybnphUXpUejNMa0UxS3Z3V2Nm?oc=5","date":"2025-05-06","type":"pipeline","source":"The Chronicle-Journal","summary":"Silence Therapeutics Welcomes Tim McInerney to Board of Directors - The Chronicle-Journal","headline":"Silence Therapeutics Welcomes Tim McInerney to Board of Directors - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1NRWdqcTM2amZVVWdPbm5ZVWJINFlhcTlweWVMQmxjcU13ZWdlQkNFcGZUS3RyUDhpa1FndG5ZS25Sc3JrdWVWMUttcWx0bzRiWllN?oc=5","date":"2025-02-27","type":"trial","source":"FirstWord Pharma","summary":"Silence delays zerlasiran Phase III launch as it scouts for partners - FirstWord Pharma","headline":"Silence delays zerlasiran Phase III launch as it scouts for partners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNOTZEdUlVWWlWbXM3NEZjSDgyY2g2a3ZpejlDbFB2WlpFSEdqN2tGb1U1cTJiT2FMWG5Wb0xFN2dseFNZdWlQVi00djY4STk2Z2FYV2pQNFZVM1p0ek41LWRRcGZUOWRXWV8zZk9oLWwxdWtHc0FibE02MVU5WVRLMkV2SEh4S3NxLTJsWFlFOFNidTVkTk14VldSdUloSUNkY3hvenVKT0p4aEdt?oc=5","date":"2024-06-24","type":"pipeline","source":"Contract Pharma","summary":"Silence Therapeutics Receives $2M Milestone Payment from Hansoh - Contract Pharma","headline":"Silence Therapeutics Receives $2M Milestone Payment from Hansoh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNdmpONjEzSkhLbU9kNkJKVTBkNzJ3YkVXbzJkbUVkcWFLTzRYb0xydDdUVzVhdTZtenlmOFpYNWc2UDBPZlRjYTB3RGFaaVZnYlh4NUVqWTR1a29mWUpTYUJ4bVQyT2NCN3RhVzhSNWJPdTA3T3lyeDBEWnRhRjFoMjZEVGhoZUdBT0huSVZhNWJIX1Bfemx1OW9kb09UZGJTUUxIZXAyRmJkQjhiY2tMZjV3bEdLaVNrMi12d3h0NXB0NkRnaXdtcWlTTTRMdGR4Yms1MUxkNGxWX3k0QlVuWHNKSEtaWlREZXhCTFluQ3QxYVY2VktNYi03VF82clpaQXk2OXo3Vi01Z3JBZkpNSzBoejFPUUtRbUp0SlVTZUgtUQ?oc=5","date":"2019-07-18","type":"deal","source":"PR Newswire","summary":"Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases - PR Newswire","headline":"Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Compleme","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":3,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}